|

Vutiglabridin Clinical Trials

2 actively recruiting trials

Also known as: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol, HSG4112, HSG4112,2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol

Pipeline

Phase 2: 2

Top Sponsors

  • Glaceum2

Indications

  • Knee Osteoarthritis (Knee OA)1
  • Parkinson's Disease1
  • Parkinson Disease1
  • Arthritis1

Other2 trials

A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
Phase 2
A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.